Taken together, in vitro and in vivo results indicate that G6PD overexpression increases RCC cell proliferation and enhances RCC tumorigenesis, whereas G6PD silencing reduces RCC cells growth and inhibits xenograft development. Here, G6PD is linked to renal cell carcinoma.